Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) issued its earnings results on Monday. The biotechnology company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.06, Zacks reports.
Rocket Pharmaceuticals Stock Performance
Rocket Pharmaceuticals stock traded down $0.66 during trading on Monday, hitting $8.79. The stock had a trading volume of 1,489,256 shares, compared to its average volume of 1,440,665. Rocket Pharmaceuticals has a 1 year low of $8.78 and a 1 year high of $30.94. The company has a quick ratio of 6.05, a current ratio of 6.05 and a debt-to-equity ratio of 0.06. The stock's 50 day moving average is $10.89 and its two-hundred day moving average is $14.66. The stock has a market cap of $801.27 million, a price-to-earnings ratio of -3.20 and a beta of 0.98.
Wall Street Analyst Weigh In
A number of analysts have commented on the company. Jefferies Financial Group assumed coverage on Rocket Pharmaceuticals in a report on Wednesday, December 18th. They set a "buy" rating and a $29.00 price objective for the company. Chardan Capital decreased their price objective on Rocket Pharmaceuticals from $62.00 to $54.00 and set a "buy" rating for the company in a report on Friday. Wedbush assumed coverage on Rocket Pharmaceuticals in a report on Monday, December 30th. They set an "outperform" rating and a $32.00 price objective for the company. Leerink Partners decreased their price objective on Rocket Pharmaceuticals from $46.00 to $44.00 and set an "outperform" rating for the company in a report on Tuesday, November 19th. Finally, Scotiabank boosted their price objective on Rocket Pharmaceuticals from $51.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Monday. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat, Rocket Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $42.30.
Check Out Our Latest Stock Report on Rocket Pharmaceuticals
Rocket Pharmaceuticals Company Profile
(
Get Free Report)
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
Recommended Stories
Before you consider Rocket Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rocket Pharmaceuticals wasn't on the list.
While Rocket Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
